AIM ImmunoTech Inc

ASE:AIM   3:59:54 PM EDT
1.94
-0.07 (-3.48%)
Products

Aim Immunotech Inc’S Drug Ampligen Awarded FDA’S Orphan Drug Designation Status For The Treatment Of Pancreatic Cancer

Published: 12/21/2020 11:56 GMT
AIM ImmunoTech Inc (AIM) - Aim Immunotech Inc.’s Drug Ampligen Awarded FDA’s Orphan Drug Designation Status for the Treatment of Pancreatic Cancer.